Good evening and welcome to Markets Desk.
Nvidia's market cap slipped below five trillion dollars this week, but at least one analyst is framing the pullback as an entry point rather than an exit. The bull case rests on the company's near-unassailable grip on the GPU market, where its architecture remains the default infrastructure for artificial intelligence workloads globally. Competitors are years behind.
Shifting to crypto, BitMine now controls nearly five percent of all Ethereum in circulation, a concentration level that has some analysts reaching for the sell button. When a single entity accumulates that kind of dominance over a decentralized asset, it introduces custodial risk, liquidity risk, and the kind of overhang that historically weighs on price discovery. That is not a subtle warning sign.
And in the pharmacy aisle, CVS Health is repositioning its roughly nine thousand locations as dedicated access points for GLP-one medications, the blockbuster weight-loss and diabetes drugs that have reshaped pharmaceutical demand. One top Wall Street analyst sees this as a structural revenue play, arguing CVS is embedding itself into one of the fastest-growing drug categories in modern medicine before competitors can respond.
That's the tape. Markets Desk, signing off the floor.
